SPINDOC

Across TCGA pan-cancer cohorts, SPINDOC Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPINDOC data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SPINDOC Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPINDOC expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and STAD are the cancer types where SPINDOC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.830	.023	14	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPINDOC–ACC (DFS)

Open the ACC breakdown →